- All sections
- A - Human necessities
- A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
- A61P 7/02 - Antithrombotic agentsAnticoagulantsPlatelet aggregation inhibitors
Patent holdings for IPC class A61P 7/02
Total number of patents in this class: 2816
10-year publication summary
|
111
|
130
|
165
|
179
|
158
|
188
|
184
|
171
|
170
|
103
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Daiichi Sankyo Company, Limited | 1889 |
71 |
| Bristol-myers Squibb Company | 4757 |
62 |
| Bayer Pharma AG | 1009 |
33 |
| Takeda Pharmaceutical Company Limited | 2698 |
28 |
| Janssen Pharmaceutica N.V. | 3150 |
20 |
| Boehringer Ingelheim International GmbH | 4488 |
18 |
| Sunshine Lake Pharma Co., Ltd. | 630 |
18 |
| Sanofi | 4323 |
18 |
| Merck Sharp & Dohme Corp. | 2183 |
17 |
| AstraZeneca AB | 2817 |
17 |
| Bayer AG | 3560 |
17 |
| The Regents of the University of Michigan | 5030 |
16 |
| Beth Israel Deaconess Medical Center, Inc. | 851 |
16 |
| Shenzhen Salubris Pharmaceuticals Co., Ltd | 132 |
16 |
| Alexion Pharmaceuticals, Inc. | 648 |
15 |
| Inserm (institut National de La Sante et de La Recherche Medicale) | 3325 |
15 |
| Novartis AG | 10174 |
14 |
| The Regents of the University of California | 20868 |
14 |
| Omeros Corporation | 306 |
14 |
| Sichuan Haisco Pharmaceutical Co., Ltd. | 151 |
14 |
| Other owners | 2363 |